About the EMERALD Trial

The EMERALD trial was a Phase 3, randomized, open-label study evaluating the efficacy of elacestrant, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer who had previously received anti-estrogen therapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), safety, and objective response rate (ORR). The trial demonstrated a meaningful improvement in PFS with elacestrant compared to standard endocrine therapy, particularly in patients with ESR1 mutations. The safety profile was manageable and consistent with known effects of endocrine therapies. These findings were presented at the 2024 ASCO Annual Meeting and have been discussed by key opinion leaders including Dr. Paolo Tarantino and Dr. Jame Abraham, providing further clinical context and relevance to practice.